Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing surveillance of Adcetris plus AVD in untreated pediatric CD30-positive Hodgkin lymphoma
jRCT2031220244Recruiting
- Sponsor
- Takeda
- Start
- Aug 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Takeda. Primary endpoints: Percentage of participants who experienced myelosuppression, Percentage of participants who experienced peripheral neuropathy and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on jRCT2031220244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220244.